活化白介素-7受体信号驱动小鼠B细胞急性淋巴细胞白血病
研究构建表达活化型Il7r的小鼠模型,发现B细胞内在的活化型Il7r足以自发诱发B-ALL,而合并Lnk敲除或Ikaros显性负性突变可提高疾病外显率。所获小鼠白血病呈单克隆性、携带复发性Kras体细胞突变,并可在免疫健全小鼠中高效植入;磷酸化蛋白质组学显示Stat5和BCR样信号持续活化,Jak、mTOR或Syk抑制剂可在体外阻断白血病B细胞生长。
要点
- 活化型Il7r突变对B-ALL具有白血病起始作用。
- 合并Lnk缺失或Ikaros显性负性突变可提高疾病外显率。
- Jak、mTOR或Syk抑制剂可体外阻断IL7R驱动B-ALL细胞生长。
核心结论
- 活化型Il7r信号足以在小鼠中诱发B-ALL,且合并Lnk或Ikzf1改变可提高外显率。
研究设计与样本
- 构建表达活化型Il7r的B细胞内在小鼠模型,并引入Lnk敲除或Ikaros显性负性突变。
主要发现
- B细胞内在活化型Il7r小鼠自发发生B-ALL。
- 合并Lnk敲除或Ikaros显性负性突变增加疾病外显率。
- 小鼠白血病呈单克隆性并携带复发性Kras体细胞突变。
- 小鼠白血病可高效植入免疫健全小鼠。
- 磷酸化蛋白质组学显示Stat5和BCR样信号持续活化。
关键数值与推荐
- 体外以Jak、mTOR或Syk抑制剂处理可阻断活化型Il7r白血病B细胞生长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype of B-ALL often associated with genetic variants that alter cytokine receptor signaling, including mutations in the interleukin-7 receptor (IL7R). To investigate whether IL7R variants are leukemia-initiating, we built mouse models expressing activated Il7r (aIL7R). B-cell intrinsic aIL7R mice developed spontaneous B-ALL, demonstrating sufficiency of Il7r activating mutations in leukemogenesis. Concomitant introduction of a knock-out allele in the associated adapter protein Lnk (encoded by Sh2b3) or a dominant-negative variant of the transcription factor Ikaros (Ikzf1) increased disease penetrance. The resulting murine leukemias displayed monoclonality and recurrent somatic Kras mutations and efficiently engrafted into immunocompetent mice. Phosphoproteomic analyses of aIL7R leukemic cells revealed constitutive Stat5 signaling and B cell receptor (BCR)-like signaling despite the absence of surface pre-BCR. Finally, in vitro treatment of aIL7R leukemic B-cells with Jak, mTOR, or Syk inhibitors blocked growth, confirming that each pathway is active in this mouse model of IL7R-driven B-ALL.
引用
- Thomas KR, Allenspach EJ, Camp ND, et al. Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice. Leukemia. 2021. PMID: 34193976. doi:10.1038/s41375-021-01326-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。